产品说明书
BD-1047 2HBr
 |
同义名 : | BD-1047 dihydrobromide;BD 1047 (hydrobromide);BD-1047 HBr |
| CAS号 : | 138356-21-5 | |
| 货号 : | A777046 | |
| 分子式 : | C13H22Br2Cl2N2 | |
| 纯度 : | 98% | |
| 分子量 : | 437.041 | |
| MDL号 : | MFCD00792739 | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 25 mg/mL(57.2 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 25 mg/mL(57.2 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | BD-1047 Dihydrobromide is a selective functional antagonist of sigma-1 receptor, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia. BD 1047 did not decrease amphetamine-induced hyperactivity in mice in a statistically significant manner. Likewise, it did not modify the hyperactivity induced by NMDA receptor antagonists, phencyclidine, memantine or dizocilpine. On the other hand, BD 1047 (1-10 mg/kg; i.p.) attenuated apomorphine-induced climbing in mice and phencyclidine-induced head twitches in rats, like rimcazole and panamesine did[3]. BD-1047 Dihydrobromide prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells. BD-1047 attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity[4]. Intrathecal (i.t.) pretreatment with the selective sigma-1 receptor antagonist, BD-1047 dihydrobromide (10-100 nmol) dose dependently reduced formalin-induced pain behaviors in second phase, but not first phase, of the formalin test. I.t. injection of BD-1047 also reduced formalin-evoked Fos expression and pNR1 at the protein kinase C-dependent site, serine-896 (Ser896) and the protein kinase A-dependent site, serine-897 (Ser897) in spinal dorsal horn.i.t[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.29mL 0.46mL 0.23mL |
11.44mL 2.29mL 1.14mL |
22.88mL 4.58mL 2.29mL |
| 参考文献 |
|---|